Last Friday, shares in Pasadena, California headquartered Arrowhead Pharmaceuticals Inc. ended the session 6.06% lower at $1.55. The stock recorded a trading volume of 2.66 million shares, which was above its three months average volume of 1.75 million shares. The Company's shares have advanced 7.64% in the last month. The stock is trading 57.63% below its 50-day moving average. Moreover, shares of Arrowhead Pharma, which develops novel drugs to treat intractable diseases in the US, have a Relative Strength Index (RSI) of 31.79.
On December 14th, 2016, Arrowhead reported revenue of $158.33 thousand for FY16, compared to revenue of $382.00 thousand for FY15. The Company's FY16 net loss decreased to $81.72 million, or $1.34 per diluted share, from net loss of $91.94 million, or $1.60 per diluted share, in FY15. The free research report on ARWR is available at:
New York headquartered Intra-Cellular Therapies Inc.'s stock declined 2.77%, to close the day at $15.09 with a total trading volume of 476,224 shares. The Company's shares have advanced 8.25% in the past month. The stock is trading 7.24% above its 50-day moving average. Additionally, shares of Intra-Cellular Therapies, which discovers and develops small molecule drugs for the treatment of neuropsychiatric and neurologic disorders within the central nervous system, have an RSI of 50.72.
On November 09th, 2016, Intra-Cellular Therapies reported a net loss of $30.3 million, or $0.70 per share (basic and diluted), for Q3 2016 compared to a net loss of $32.2 million, or $0.91 per share (basic and diluted), for Q3 2015. The Company's cash and investments totaled $537.8 million at September 30th, 2016. This amount included short-term borrowing of $125 million that was repaid in October 2016. The resulting net cash available for operations at September 30th, 2016, was $412.8 million, compared to $475.2 million at December 31st, 2015.
On December 16th, 2016, research firm Cantor Fitzgerald initiated an 'Overweight' rating on the Company's stock. The complimentary report on ITCI can be downloaded at:
Shares in Rockville, Maryland headquartered Synthetic Biologics Inc. recorded a trading volume of 2.11 million shares at the close of the last trading session, which was above their three months average volume of 991,500 shares. The stock ended the day 0.74% higher at $0.76. The Company's shares are trading below their 50-day moving average by 28.29%. Furthermore, shares of Synthetic Biologics, which engages in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases in the US, have an RSI of 36.89.
On December 13th, 2016, Synthetic Biologics announced that the US Patent Office has granted US Patent No. 9,512,204 which provides composition of matter coverage for SYN-005, the Company's preclinical drug candidate designed to treat or prevent the development of Pertussis (whooping cough), especially in infants. The exclusivity provided by this new patent has an expiration date of 2035, which does not include a potential patent term extension. Visit us today and download our complete research report on SYN for free at:
Cambridge, Massachusetts headquartered CoLucid Pharmaceuticals Inc.'s shares finished Friday's session 1.22% lower at $36.40. A total volume of 121,243 shares was traded. The stock has advanced 2.97% in the last one month and 334.89% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 3.52% and 100.56%, respectively. Furthermore, shares of CoLucid Pharma, which develops small molecules for the acute treatment of migraine, have an RSI of 51.16.
On November 14th, 2016, CoLucid Pharmaceuticals announced that over 50% of the 2,968 migraine patients expected to enroll in the Company's SPARTAN trial, the second of two pivotal Phase 3 clinical trials, have now been randomized. SPARTAN is being conducted under a Special Protocol Assessment agreement with the US FDA. Top-line results from SPARTAN are expected in H2 2017.
On December 15th, 2016, research firm Barclays initiated an 'Overweight' rating on the Company's stock, with a target price of $45 per share. Get free access to your technical report on CLCD at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA